.Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P02C_AntinematodalAgents.P02CA03_Albendazole.Albendazole .Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P02C_AntinematodalAgents.P02CA03_Albendazole.Albendazole| name: | Albendazole |
| ATC code: | P02CA03 | route: | oral |
| n-compartments | 1 |
Albendazole is an anthelmintic drug used to treat a broad range of parasitic worm infestations, including neurocysticercosis, hydatid disease, giardiasis, and soil-transmitted helminthiases. It disrupts the microtubule formation in parasites, leading to their immobilization and death. Albendazole is widely approved and used globally for these indications.
Pharmacokinetic parameters reported in healthy adult volunteers after a single 400 mg oral dose, under fasting conditions.
Whittaker, C, et al., & Boussinesq, M (2022). Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis. PLoS neglected tropical diseases 16(10) e0010497–None. DOI:10.1371/journal.pntd.0010497 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36306320
Fimbo, AM, et al., & Aklillu, E (2023). Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania. CPT: pharmacometrics & systems pharmacology 12(12) 1884–1896. DOI:10.1002/psp4.13038 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37638539
Pettarin, M, et al., & Kostewicz, ES (2020). A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 155 105552–None. DOI:10.1016/j.ejps.2020.105552 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32937212